AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs

10/07/2026 – AB Science today provides an update on its clinical development program and announces the discontinuation of certain non-priority clinical studies in order to focus on two clinical programs, the AB8939 program for AML and the masitinib program for ALS